Sectors
DRTS
Alpha Tau Medical Ltd.
15.24
2 x 11.16
2 x 20.16
bid
ask
-
0.25
1.61%
2 @ 07:30 PM
15.60 +0.36 (2.36%)
| Ytd | 207.88% | |
| 1y | 300.00% |
15.10
day range
15.63
3.47
52 week range
15.49
| Open | 15.60 | Prev Close | 15.49 | Low | 15.10 | High | 15.63 | Mkt Cap | 1.41B |
| Vol | 624.26K | Avg Vol | 678.26K | EPS | -1.04 | P/E | N/A | Forward P/E | -28.51 |
| Beta | 1.21 | Short Ratio | 5.11 | Inst. Own | 9.09% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-19 | 50-d Avg | 13.66 | 200-d Avg | 9.22 | 1yr Est | 17.80 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-19 | 2026-09 | -0.14 | N/A | N/A | N/A |
| 2026-08-10 | 2026-06 | -0.14 | -0.5 | -0.36 | -254.91% |
| 2026-05-18 | 2026-03 | -0.13 | -0.26 | -0.13 | -100.00% |
| 2026-03-09 | 2025-12 | -0.13 | -0.14 | -0.01 | -7.69% |
| 2025-11-20 | 2025-09 | -0.12 | -0.14 | -0.02 | -16.67% |
| 2025-08-11 | 2025-06 | -0.12 | -0.13 | -0.01 | -8.33% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-09-03 | Barclays | Upgrade | Overweight | Overweight |
| 2026-08-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-07-22 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-07-16 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-06-04 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-06-04 | Barclays | Upgrade | Overweight | Overweight |
Profile
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-08-20 | LEVY RAPHI | Chief Financial Officer | 90.18K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Gem Investment Advisors, LLC | 1.43M | 21.86M | 2.07% |
| 2026-06-29 | HighTower Advisors, LLC | 874.99K | 13.33M | 1.26% |
| 2026-06-29 | Boothbay Fund Management, LLC | 773.48K | 11.79M | 1.12% |
| 2026-06-29 | Aquamarine Financial (cayman) Ltd | 721.50K | 11.00M | 1.04% |
| 2026-06-29 | Pier Capital, LLC | 691.94K | 10.55M | 1.00% |
| 2026-06-29 | UBS Group AG | 642.26K | 9.79M | 0.93% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-08-30 | ARK ETF Trust-ARK Israel Innovative Technology ETF | 184.38K | 2.81M | 0.27% |
| 2026-08-30 | RBB Fund, Inc.-Adara Smaller Companies Fund | 134.70K | 2.05M | 0.19% |
| 2026-07-30 | Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 53.40K | 813.80K | 0.08% |
| 2026-04-29 | Dunham Funds-Dunham Small Cap Growth Fund | 27.11K | 413.17K | 0.04% |
| 2026-06-29 | Tidal Trust II-Even Herd Long Short ETF | 24.66K | 375.77K | 0.04% |
| 2026-06-29 | 360 Funds-Timber Point Global Allocations Fund | 20.00K | 304.80K | 0.03% |